Antiangiogenic therapy for ischemic retinopathies

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 6, 2012, Pages

  Al Latayfeh, Motasem ^a,b   Silva, Paolo S ^a,b   Sun, Jennifer K ^a,b   Aiello, Lloyd Paul ^a,b  

^a JOSLIN DIABETES CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOPOIETIN; BEVACIZUMAB; BEVASIRANIB; CHORIONIC GONADOTROPIN; CORTICOTROPIN; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR 2; IMMUNOGLOBULIN F (AB) FRAGMENT; PEGAPTANIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIGMENT EPITHELIUM DERIVED FACTOR; PIOGLITAZONE; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE C; PROTEIN KINASE C LAMBDA; PROTEIN TYROSINE PHOSPHATASE; RANIBIZUMAB; ROSIGLITAZONE; SMALL INTERFERING RNA; SOMATOMEDIN; SOMATOMEDIN C; TIE 1 RECEPTOR; TRIAMCINOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN A; VERTEPORFIN;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD VESSEL PERMEABILITY; BRANCH RETINAL VEIN OCCLUSION; CELL STIMULATION; CENTRAL RETINA VEIN OCCLUSION; CHOROIDAL NEOVASCULAR MEMBRANE; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; HUMAN; LASER COAGULATION; NEOVASCULAR GLAUCOMA; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PHASE 3 CLINICAL TRIAL (TOPIC); PROLIFERATIVE RETINOPATHY; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA ISCHEMIA; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETINA VEIN OCCLUSION; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VITRECTOMY; DRUG ANTAGONISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; RETINA MACULA DEGENERATION;

ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; GLAUCOMA, NEOVASCULAR; HUMANS; LASER COAGULATION; MACULAR DEGENERATION; RETINAL NEOVASCULARIZATION; RETINAL VEIN OCCLUSION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY;

EID: 84876727599     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a006411     Document Type: Article

References (137)

1. Abhary S, Burdon KP, Casson RJ, Goggin M, Petrovsky NP, Craig JE. 2010. Association between erythropoietin gene polymorphisms and diabetic retinopathy. Arch Ophthalmol 128: 102-106.
2. Abraham P, Yue H, Wilson L. 2010. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 150: 315-324.
3. Adamis AP, Aiello LP, D'Amato RA. 1999. Angiogenesis and ophthalmic disease. Angiogenesis 3: 9-14.
4. Age-Related Eye Disease Study Research Group. 2000. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology 107: 2224-2232.
5. Age-Related Eye Disease Study Research Group. 2001. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, β carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119: 1417-1436.
6. Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R. 2009. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: A randomized clinical trial. Ophthalmology 116: 1943-1948.
7. Aiello LP. 2002. The potential role of PKC β in diabetic retinopathy and macular edema. Surv Ophthalmol 47 (Suppl 2): S263-S269.
8. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE. 1994. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487.
9. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE. 1995. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci 92: 10457-10461.
10. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, King GL, et al. 1997. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes 46: 1473-1480.
11. Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, Vignati L, Zhi XE. 2006. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 113: 2221-2230.
12. Aljada A, O'Connor L, Fu YY, Mousa SA. 2008. PPAR γ ligands, rosiglitazone and pioglitazone, inhibit bFGF-and VEGF-mediated angiogenesis. Angiogenesis 11: 361-367.
13. Altinsoy HI, Mutlu FM, Gungor R, Sarici SU. 2010. Combination of laser photocoagulation and intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 9: 1-5.
14. Andreoli CM, Miller JW. 2007. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 18: 502-508.
15. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. 1999. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 274: 23463-23467.
16. Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, Yancopoulos GD, Isner JM. 1998. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 83: 233-240.
17. Avery RL. 2006. Regression of retinal and iris neovascularization after intravitreal bevacizumab. (Avastin) treatment. Retina 26: 352-354.
18. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, GiustMJ, Wendel R, Patel A. 2006. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113: 1695.
19. Bashshur ZF, Haddad ZA, Schakal AR, Jaafar RF, Saad A, Noureddin BN. 2009. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: The second year of a prospective study. Am J Ophthalmol 148: 59-65.
20. Beatty S, Koh H, Phil M, Henson D, Boulton M. 2000. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 45: 115-134.
21. Beutel J, Ziemssen F, Luke M, Partsch M, Bartz-Schmidt KU, Gelisken F. 2010. Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: One-year results. Int Ophthalmol 30: 15-22.
22. Boyd SR, Zachary I, Chakravarthy U, Allen GJ, Wisdom GB, Cree IA, Martin JF, Hykin PG. 2002. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 120: 1644-1650.
23. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. 2009. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 116: 1731-1739.
24. Bressler NM. 2001. Treatment of age-related macular degeneration with photodynamic therapy: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 119: 198-207.
25. Bressler NM, Bressler SB, Fine SL. 1988. Age-related macular degeneration. Surv Ophthalmol 32: 375-413.
26. Brouzas D, Charakidas A, Moschos M, Koutsandrea C, Apostolopoulos M, Baltatzis S. 2009. Bevacizumab (Avastin) for the management of anterior chamber neovascularization and neovascular glaucoma. Clin Ophthalmol 3: 685-688.
27. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. 2009. ANCHOR Study Group: Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 116: 57-65.
28. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, RubioRG, Murahashi WY. 2010. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117: 1124-1133.
29. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY. 2011. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-Month outcomes of a phase III study. Ophthalmology 118: 1594-1602.
30. Brown DM, Heier JS, Ciulla T, Benz M, Abraham P, Yancopoulos G, Stahl N, Ingerman A, Vitti R, Berliner AJ, et al. 2011. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology 118: 1089-1097.
31. Cai J, Kehoe O, Smith GM, Hykin P, Boulton ME. 2008. The angiopoietin/Tie-2 system regulates pericyte survival and recruitment in diabetic retinopathy. Invest Ophthalmol Vis Sci 49: 2163-2171.
32. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG. 2010. Ranibizumab for macular edema following branch retinal vein occlusion: Six-month primary end point results of a phase III study. Ophthalmology 117: 1102-1112.
33. Carlini RG, Reyes AA, Rothstein M. 1995. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 47: 740-745.
34. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. 2011. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364: 1897-1908.
35. Chen J, Connor KM, Aderman CM, Willett KL, Aspegren OP, Smith LE. 2009. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci 50: 1329-1335.
36. Chew EY, Ferris FL III., Csaky KG, Murphy RP, Agron E, Thompson DJ, Reed GF, Schachat AP. 2003. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: The early treatment diabetic retinopathy follow-up study. Ophthalmology 110: 1683-1689.
37. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL III. 2005. Age-Related Eye Disease Study Research Group: Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology 112: 533-539.
38. Congdon N, O'Colmain B, Klaver CC, Klein R, Munoz B, Friedman DS, Kempen J, Taylor HR, Mitchell P. 2004. Eye Diseases Prevalence Research Group: Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122: 477-485.
39. Cugati S, Wang JJ, Rochtchina E, Mitchell P. 2006. Ten-year incidence of retinal vein occlusion in an older population: The Blue Mountains Eye Study. Arch Ophthalmol 124: 726-732.
40. Davidorf FH, Mouser JG, Derick RJ. 2006. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina 26: 354-356.
41. Davis MD, Sheetz MJ, Aiello LP, Milton RC, Danis RP, Zhi X, Girach A, JimenezMC, Vignati L. 2009. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema. Invest Ophthalmol Vis Sci 50: 1-4.
42. Do DV, Nguyen QD, Shah SM, Browning DJ, Haller JA, Chu K, Yang K, Cedarbaum JM, Vitti RL, Ingerman A, Campochiaro PA. 2009. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. Br J Ophthalmol 93: 144-149.
43. Donoso LA, Kim D, Frost A, Callahan A, Hageman G. 2006. The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 51: 137-152.
44. Dor Y, Porat R, Keshet E. 2001. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol Cell Physiol 280: C1367-C1374.
45. Edwards AO, Ritter R III., Abel KJ, Manning A, Panhuysen C, Farrer LA. 2005. Complement factor H polymorphism and age-related macular degeneration. Science 308: 421-424.
46. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL, Friedman SM, Glassman AR, Miller KM, Sun JK, et al. 2010. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117: 1064-1077.
47. Erdol H, Turk A, Akyol N, Imamoglu HI. 2010. The results of intravitreal bevacizumab injections for persistent neovascularizations in proliferative diabetic retinopathy after photocoagulation therapy. Retina 30: 570-577.
48. Ferrara N. 2004. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 25: 581-611.
49. Ferrara N, Henzel WJ. 1989. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161: 851-858.
50. Ferrara N, Hillan KJ, Novotny W. 2005. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333: 328-335.
51. Ferris FL III., Davis MD, Aiello LM. 1999. Treatment of diabetic retinopathy. N Engl J Med 341: 667-678.
52. Fong DS, Ferris FL III., Davis MD, Chew EY. 1999. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. Am J Ophthalmol 127: 137-141.
53. Gao BB, Clermont A, Rook S, Fonda SJ, Srinivasan VJ, Wojtkowski M, FujimotoJG, Avery RL, Arrigg PG, Bursell SE, et al. 2007. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 13: 181-188.
54. Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, Clermont A, Leitges M, Marette A, Aiello LP, Kern TS, King GL. 2009. Activation of PKC-δ and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med 15: 1298-1306.
55. Gharbiya M, Giustolisi R, Allievi F, Fantozzi N, Mazzeo L, Scavella V, GabrieliCB. 2010. Choroidal neovascularization in pathologic myopia: Intravitreal ranibizumab versus bevacizumab-A randomized controlled trial. Am J Ophthalmol 149: 458-464.
56. Girach A, Aiello LP, Milton RC, Davis MD, Danis RP, Zhi X, Sheetz MJ, Vignati L, PKC-DRS2 Study Group. 2009. Sustained moderate visual loss as a predictive end point for visual loss in non-proliferative diabetic retinopathy. Eye (Lond) 23: 209-214.
57. Gragoudas ES, Adamis AP, Cunningham ET Jr., Feinsod M, Guyer DR. 2004. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805-2816.
58. Gregori NZ, Gaitan J, Rosenfeld PJ, Puliafito CA, Feuer W, Flynn HW, BerrocalAM, Al Attar L, Dubovy S, Smiddy WE, et al. 2008. Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion. Retina 28: 1325-1337.
59. Gupta A, Muecke JS. 2008. Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin). Retina 28: 964-968.
60. Hayashi K, Ohno-Matsui K, Teramukai S, Shimada N, Moriyama M, Hayashi W, Yoshida T, Tokoro T, Mochizuki M. 2009. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Am J Ophthalmol 148: 396-408.
61. Hayreh SS, Zimmerman MB, Podhajsky P. 1994. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol 117: 429-441.
62. Heier JS, Boyer D, Nguyen QD, Marcus D, Roth DB, Yancopoulos G, Stahl N, Ingerman A, Vitti R, Berliner AJ, et al. 2011. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 118: 1098-1106.
63. Henkind P, Wise GN. 1974. Retinal neovascularization, collaterals, and vascular shunts. Br J Ophthalmol 58: 413-422.
64. Hernandez-Da Mota SE. 2010. Nunez-Solorio SM: Experience with intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy. Eur J Ophthalmol 20: 1047-1052.
65. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, LeidichR, Hylton D, Burova E, et al. 2002. VEGF-trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci 99: 11393-11398.
66. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. 1991. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5: 1806-1814.
67. Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F, Tano Y. 2009. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 147: 94-100.
68. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH. 2009. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 127: 1101-1114.
69. Jager RD, Mieler WF, Miller JW. 2008. Age-related macular degeneration. N Engl J Med 358: 2606-2617.
70. Jelkmann W. 1992. Erythropoietin: Structure, control of production, and function. Physiol Rev 72: 449-489.
71. Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU. 2006. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 26: 1006-1013.
72. Kaiser PK. 2006. Antivascular endothelial growth factor agents and their development: Therapeutic implications in ocular diseases. Am J Ophthalmol 142: 660-668.
73. Klein R, Klein BE, Moss SE. 1984. Visual impairment in diabetes. Ophthalmology 91: 1-9.
74. Klein R, Peto T, Bird A, Vannewkirk MR. 2004. The epidemiology of age-related macular degeneration. Am J Ophthalmol 137: 486-495.
75. Law JC, Recchia FM, Morrison DG, Donahue SP, Estes RL. 2010. Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. JAAPOS 14: 6-10.
76. Macular Photocoagulation Study Group. 1991. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 109: 1232-1241.
77. Macular Photocoagulation Study Group. 1993. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Arch Ophthalmol 111: 1200-1209.
78. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, et al. 1997. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60.
79. Mansour AM, Arevalo JF, Ziemssen F, Mehio-Sibai A, Mackensen F, Adan A, Chan WM, Ness T, Banker AS, Dodwell D, et al. 2009. Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol 148: 310-316.
80. Mathews MK, Merges C, McLeod DS, Lutty GA. 1997. Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy. Invest Ophthalmol Vis Sci 38: 2729-2741.
81. McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, Kowalski JW, Nguyen HP, Wong TY. 2010. Natural history of central retinal vein occlusion: An evidence-based systematic review. Ophthalmology 117: 1113-1123.
82. Mendrinos E, Donati G, Pournaras CJ. 2009. Rapid and persistent regression of severe new vessels on the disc in proliferative diabetic retinopathy after a single intravitreal injection of pegaptanib. Acta Ophthalmol 87: 683-684.
83. Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS, Folkman J, Dvorak HF, Brown LF, Berse B, et al. 1994. Vascular endothelial growth factor/vascular permeability factor is temporally and spacially correlated with ocular angiogenesis in a primate model. Am J Pathol 145: 574-584.
84. Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, Laqua H, BarbazettoI, Zografos L, Piguet B, Donati G, Lane AM, et al. 1999. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: Results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 117: 1161-1173.
85. Mirshahi A, Roohipoor R, Lashay A, Mohammadi SF, Abdoallahi A, Faghihi H. 2008. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: A randomized double-masked clinical trial. Eur J Ophthalmol 18: 263-269.
86. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, SchlingemannRO, Sutter F, Simader C, Burian G, Gerstner O, et al. 2011. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118: 615-625.
87. Modarres M, Nazari H, Falavarjani KG, Naseripour M, Hashemi M, ParvareshMM. 2009. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol 19: 848-852.
88. Murata T, Ishibashi T, Khalil A, Hata Y, Yoshikawa H, Inomata H. 1995. Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res 27: 48-52.
89. Nguyen QD, Shah SM, Browning DJ, Hudson H, Sonkin P, Hariprasad SM, KaiserP, Slakter JS, Haller J, Do DV, et al. 2009. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology 116: 2141-2148.
90. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, Abraham P, Campochiaro PA. 2009. Primary end point (six months) results of the Ranibizumab for Edema of the Macula in Diabetes (READ-2) study. Ophthalmology 116: 2175-2181.
91. Noma H, Funatsu H, Mimura T, Harino S, Hori S. 2010. Aqueous humor levels of vasoactive molecules correlate with vitreous levels and macular edema in central retinal vein occlusion. Eur J Ophthalmol 20: 402-409.
92. Nowak JZ. 2006. Age-related macular degeneration (AMD): Pathogenesis and therapy. Pharmacol Rep 58: 353-363.
93. Ogata N, Tombran-Tink J, Nishikawa M, Nishimura T, Mitsuma Y, Sakamoto T, Matsumura M. 2001. Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment. Am J Opthalmol 132: 378-382.
94. Oshima Y, Shima C, Wakabayashi T, Kusaka S, Shiraga F, Ohji M, Tano Y. 2009. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology 116: 927-938.
95. Ozaki H, Yu AY, Della N, Ozaki K, Luna JD, Yamada H, Hackett SF, Okamoto N, Zack DJ, Semenza GL, Campochiaro PA. 1999. Hypoxia inducible factor-1α is increased in ischemic retina: Temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci 40: 182-189.
96. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, MosesMA, Kilroy S, Duensing S, Fletcher C, et al. 2002. PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110: 923-932.
97. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. 1998. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 105: 412-416.
98. Phipps JA, Clermont AC, Sinha S, Chilcote TJ, Bursell SE, Feener EP. 2009. Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability. Hypertension 53: 175-181.
99. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. 1995. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci 92: 905-909.
100. PKC DRS, Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, VignatiL, Zhi XE. 2006. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 113: 2221-2230.
101. PKC-DRS Study Group. 2005. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: Initial results of the Protein Kinase C β Inhibitor Diabetic Retinopathy study (PKC-DRS) multicenter randomized clinical trial. Diabetes 54: 2188-2197.
102. PKC-DMES Study Group. 2007. Effect of ruboxistaurin in patients with diabetic macular edema: Thirty-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol 125: 318-324.
103. Prager F, Michels S, Kriechbaum K, Georgopoulos M, Funk M, Geitzenauer W, Polak K, Schmidt-Erfurth U. 2009. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 93: 452-456.
104. Praidou A, Androudi S, Brazitikos P, Karakiulakis G, Papakonstantinou E, Dimitrakos S. 2010. Angiogenic growth factors and their inhibitors in diabetic retinopathy. Curr Diabetes Rev 6: 304-312.
105. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N. 2008. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145: 239-248.
106. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, Nico B, Roncali L, Dammacco F. 1999. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93: 2627-2636.
107. Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW, Nguyen HP, Wang JJ, Wong TY. 2010. Natural history of branch retinal vein occlusion: An evidence-based systematic review. Ophthalmology 117: 1094-1101.
108. Rojas M, Zhang W, Lee DL, Romero MJ, Nguyen DT, Al Shabrawey M, Tsai NT, Liou GI, Brands MW, Caldwell RW, Caldwell RB. 2010. Role of IL-6 in angiotensin II-induced retinal vascular inflammation. Invest Ophthalmol Vis Sci 51: 1709-1718.
109. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. 2005a. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36: 331-335.
110. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD, Greene WL, Shams N. 2005b. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 112: 1048-1053.
111. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. 2006. MARINA Study Group: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431.
112. Ruckman J, Green LS, Beeson J, Waugh S, Gillette WL, Henninger DD, Claesson-Welsh L, Janjic N. 1998. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor. (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 273: 20556-20567.
113. Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, et al. 2007. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114: 1860-1867.
114. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M. 2009. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 127: 1115-1128.
115. Semenza GL. 2003. Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med 54: 17-28.
116. Shen LQ, Child A, Weber GM, Folkman J, Aiello LP. 2008. Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol 126: 793-799.
117. Simo R, Carrasco E, Garcia-Ramirez M, Hernandez C. 2006. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev 2: 71-98.
118. Singerman L. 2009. Combination therapy using the small interfering RNA bevasiranib. Retina 29: S49-S50.
119. Siqueira RC, Costa RA, Scott IU, Cintra LP, Jorge R. 2006. Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy. Acta Ophthalmol Scand 84: 834-835.
120. Stefansson E. 2006. Ocular oxygenation and the treatment of diabetic retinopathy. Surv Ophthalmol 51: 364-380.
121. Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS. 2011. Study Group: A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 118: 1107-1118.
122. Sun JK, Aiello LP, Miller JW. 2008. Proliferative diabetic retinopathy. InPrinciples and practice of ophthalmology, 3rd ed. (ed. Albert DM), pp. 1807-1827. W. B. Saunders Co., Philadelphia.
123. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD. 1996. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171-1180.
124. Takagi H, Koyama S, Seike H, Oh H, Otani A, Matsumura M, Honda Y. 2003. Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization. Invest Ophthalmol Vis Sci 44: 393-402.
125. Takahashi K, Saishin Y, Saishin Y, King AG, Levin R. 2009. Campochiaro PA: Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. Arch Ophthalmol 127: 494-499.
126. The Central Vein Occlusion Study Group. 1997. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 115: 486-491.
127. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA. 1991. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266: 1 11947-11954.
128. Tonello M, Costa RA, Almeida FP, Barbosa JC, Scott IU, Jorge R. 2008. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 86: 385-389.
129. Tong Z, Yang Z, Patel S, Chen H, Gibbs D, Yang X, Hau VS, Kaminoh Y, HarmonJ, Pearson E, et al. 2008. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci 105: 6998-7003.
130. Verteporfin in Photodynamic Therapy Study Group. 2001. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 131: 541-560.
131. Votruba M, Gregor Z. 2001. Neovascular age-related macular degeneration: Present and future treatment options. Eye (Lond) 15: 424-429.
132. Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, Otori Y, Kamei M, Kusaka S, Tano Y. 2008. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 115: 1571-1580.
133. Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, Suzuma I, Ohashi H, Ojima T, Murakami T, et al. 2005. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 353: 782-792.
134. Wiegand TW, Rogers AH, McCabe F, Reichel E, Duker JS. 2009. Intravitreal bevacizumab (Avastin) treatment of choroidal neovascularisation in patients with angioid streaks. Br J Ophthalmol 93: 47-51.
135. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, Takagi H, NewsomeWP, Jirousek MR, King GL. 1996. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 98: 2018-2026.
136. Xiong SQ, Xia XB, Xu HZ, Jiang J. 2009. Suppression of retinal neovascularization by small-interference RNA targeting erythropoietin. Ophthalmologica 223: 306-312.
137. Zhang SX, Wang JJ, Gao G, Parke K, Ma JX. 2006. Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol 37: 1-12.